North Chicago, IL, United States · Est. 2012 · 50,000 employees
Research-driven biopharmaceutical company focused on advanced therapies for complex diseases.
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Orange Book Patents
Across 18 drugs with upcoming expirations
Pipeline
By Phase
62 drugs in development
By Therapeutic Area
top 6
R&D Momentum
98/100
Pipeline Velocity
80/100
Trial Completion Rate
86/100
Pipeline Concentration
20/100
Pipeline Freshness
71/100
Strategic Signals
Activity
Last 14 days
A Phase 2 Platform Basket Study Evaluating Advanced Therapies in Subjects With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis
A Phase 1 Open-Label, Two-Period Study to Evaluate the Impact of Multiple Doses of Itraconazole on the Pharmacokinetics of Nacresertib in Healthy Adult Subjects
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of ABBV-1758 in Participants With Alzheimer's Disease
An Open-Label, Randomized, Controlled, Global Phase 3 Study Comparing Telisotuzumab Adizutecan (ABBV-400) Plus Bevacizumab to LONSURF (Trifluridine and Tipiracil) Plus Bevacizumab in Subjects With Refractory Metastatic Colorectal Cancer
A Phase 2 Dose-Finding Study to Assess the Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities
A Phase 3 Randomized, Placebo-controlled, Double-blind Study to Evaluate Efficacy and Safety of Upadacitinib in Pediatric Subjects With Severe Alopecia Areata
A Multicenter, Double-masked, Randomized Study to Compare the Efficacy and Safety of the ABBV-444 Tear Formulation With REFRESH OPTIVE® Unit Dose in Patients With Dry Eye Disease
A Phase 3, Multi-Center Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Risankizumab With Open-Label Induction, Randomized Double-Blind Maintenance, and Open-Label Long-Term Extension Periods in Pediatric Subjects (2 to < 18 Years of Age) With Moderately to Severely Active Ulcerative Colitis
An Operationally Seamless Phase 2b/3, Multicenter, Randomized, Masked, Sham-controlled Study to Evaluate the Efficacy and Safety of Surabgene Lomparvovec (Sura-vec) Delivered Via Suprachoroidal Space (SCS) Injection Targeting Subjects With Diabetic Retinopathy Without Center Involved-Diabetic Macular Edema (CI-DME) (NAAVIGATE)
A Phase 3 Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin (ABBV-399) Versus Docetaxel in Subjects With Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer
A Phase 1 Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of ABBV-932 in Adult Subjects With Bipolar Disorder
Details
Company Overview
$310.0B
Mkt Cap
$54.3B
Revenue
$5.5B
Cash
Therapeutic Focus
Recent SEC Filings
FORM 8-K
FORM 8-K
FORM 8-K
8-K
8-K
Pipeline
Regulatory
Vraylar — VRAYLAR
Application NDA204370 (NDA)
Rinvoq — RINVOQ LQ
Application NDA218347
Rinvoq — RINVOQ
Application NDA211675
Qulipta — QULIPTA
Application NDA215206
Zolymbus — ZOLYMBUS
Application NDA217307 (NDA)
Skyrizi — SKYRIZI
Application BLA761262
Skyrizi — SKYRIZI
Application BLA761105
Lexapro — ESCITALOPRAM
Application NDA219130 (NDA)
FORM 8-K
Accession: 0001104659-26-104940
FORM 8-K
Accession: 0001104659-26-098367
FORM 8-K
Accession: 0001104659-26-091269
8-K
Accession: 0001551152-26-000023
8-K
Accession: 0001551152-26-000021
Rinvoq — RINVOQ LQ
Application NDA218347
Rinvoq — RINVOQ
Application NDA211675
Skyrizi — SKYRIZI
Application BLA761262
Skyrizi — SKYRIZI
Application BLA761105
FORM 8-K
Accession: 0001104659-26-076067
Skyrizi — SKYRIZI
Application BLA761105
Skyrizi — SKYRIZI
Application BLA761262
Venclexta — VENCLEXTA
Application NDA208573
Skyrizi — SKYRIZI
Application BLA761105
Skyrizi — SKYRIZI
Application BLA761262
Skyrizi — SKYRIZI
Application BLA761105
Skyrizi — SKYRIZI
Application BLA761262
Venclexta — VENCLEXTA
Application NDA208573
AbbVie Inc. (ABBV) (CIK 0001551152)
Accession: 001-35565
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)